NP measurement by general practitioners (GP) and diabetologists in high-risk populations such as those with hypertension or T2DM aids in identifying patients with elevated ventricular diastolic pressures in order to strengthen the initiation of preventive measures, including medicine up-titration of renin–angiotensin system antagonists or the introduction of novel therapies such as sodium/glucose cotransporter 2 inhibitors (SGLT2i), and therefore, in preventing or slowing the development of HF [35,36,37]. The gene discussed is REN; the disease is hydrops fetalis.